Hepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas
Hepatitis occurred in 28.75% of HBsAg-positive and 17.85% of HBsAg-negative patients on everolimus. HBVr was common in HBsAg-positive patients but rare in HBsAg-negative individuals. HBV screening and liver function monitoring are critical for patients with past or current HBV infection receiving everolimus, especially in endemic areas.
Authors
- Chien-Ting Liu (ORCID: https://orcid.org/0009-0003-6209-2537)
- Pao‐Chu Wu (ORCID: https://orcid.org/0000-0001-8852-0534)
- Yi‐Hsin Yang (ORCID: https://orcid.org/0000-0002-9581-2778)
- Chung‐Yu Chen (ORCID: https://orcid.org/0000-0001-7206-3957)
- Chien-Hao Su
Institutions
- Kaohsiung Medical University (TW)
- National Health Research Institutes (TW)
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Chiayi Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-28
- DOI
- https://doi.org/10.3390/cancers16233997
- Citations
- 2
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.77